Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) has received a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $3.81.

Several brokerages have recently weighed in on EYPT. ValuEngine raised Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Zacks Investment Research raised Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Thursday, January 30th. HC Wainwright reaffirmed a “hold” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, February 4th. Finally, Laidlaw began coverage on Eyepoint Pharmaceuticals in a research note on Monday, November 4th. They set a “buy” rating and a $5.00 target price for the company.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN increased its position in shares of Eyepoint Pharmaceuticals by 90.0% during the second quarter. Wells Fargo & Company MN now owns 96,945 shares of the company’s stock worth $159,000 after purchasing an additional 45,922 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Eyepoint Pharmaceuticals by 225.7% during the second quarter. Bank of New York Mellon Corp now owns 149,870 shares of the company’s stock worth $245,000 after purchasing an additional 103,857 shares in the last quarter. Northern Trust Corp increased its position in shares of Eyepoint Pharmaceuticals by 44.9% during the second quarter. Northern Trust Corp now owns 167,434 shares of the company’s stock worth $275,000 after purchasing an additional 51,919 shares in the last quarter. BlackRock Inc. increased its position in shares of Eyepoint Pharmaceuticals by 298.2% during the second quarter. BlackRock Inc. now owns 4,635,930 shares of the company’s stock worth $7,602,000 after purchasing an additional 3,471,613 shares in the last quarter. Finally, Creative Planning purchased a new stake in shares of Eyepoint Pharmaceuticals during the third quarter worth approximately $47,000. Hedge funds and other institutional investors own 56.89% of the company’s stock.

Shares of EYPT stock traded down $0.07 during trading hours on Friday, hitting $1.78. 308,488 shares of the company’s stock were exchanged, compared to its average volume of 522,527. The company has a quick ratio of 4.29, a current ratio of 4.54 and a debt-to-equity ratio of 3.12. The firm has a market cap of $200.56 million, a P/E ratio of -3.07 and a beta of 1.58. The firm has a 50 day moving average of $1.71 and a two-hundred day moving average of $1.70. Eyepoint Pharmaceuticals has a fifty-two week low of $1.19 and a fifty-two week high of $2.82.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Featured Article: Municipal Bonds

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.